Relevance of hepatic lipase to the metabolism of triacylglycerol-rich lipoproteins
|
|
- Betty Jennifer Webb
- 5 years ago
- Views:
Transcription
1 1070 Biochemical Society Transactions (2003) Volume 31, part 5 Relevance of hepatic lipase to the metabolism of triacylglycerol-rich lipoproteins A. Zambon 1,S.Bertocco, N. Vitturi, V. Polentarutti, D. Vianello and G. Crepaldi Department of Medical and Surgical Sciences, Clinica Medica 1, University of Padua, Via Giustiniani, 2, Padova, Italy Abstract HL (hepatic lipase) is a glycoprotein that is synthesized and secreted by the liver, and which binds to heparan sulphate proteoglycans on the surface of sinusoidal endothelial cells and on the external surface of parenchymal cells in the space of Disse. HL catalyses the hydrolysis of triacylglycerols and phospholipids in different lipoproteins, contributing to the remodelling of VLDL (very-low-density lipoprotein) remnants, as well as IDL, LDL and HDL (intermediate-, low- and high-density lipoprotein respectively). HL deficiency in humans is associated with diminished conversion of VLDL remnants into IDL and a near-complete absence of IDL-to-LDL conversion. Remnant lipoproteins and IDL are major determinants of coronary artery disease risk, and accumulation of these lipoproteins in the presence of low HL activity might lead to increased atherosclerosis. In addition to and independently of its lipolytic activity, HL participates as a ligand in promoting the hepatic uptake of remnants and IDL particles, and the latter may represent an additional mechanism linking low HL levels to plasma accumulation of these atherogenic lipoproteins. On the other hand, high HL activity may also result in an increased atherosclerotic risk by promoting the formation of atherogenic small, dense LDL particles. Finally, HL is also synthesized by human macrophages, suggesting that, at the arterial wall site, HL may also contribute locally to promote atherosclerosis by enhancing the formation and retention in the subendothelial space of the arterial wall of VLDL remnants, IDL and small, dense LDL. In conclusion, by interfering with the metabolism of apolipoprotein B100-containing lipoproteins, HL may have pro- as well as anti-atherogenic effects. The anti- or pro-atherogenic role of HL is likely to be modulated by the concurrent presence of other lipid abnormalities (i.e. LDL-cholesterol levels), as well as by the genetic regulation of other enzymes involved in lipoprotein metabolism. Introduction Lipases are water-soluble enzymes that hydrolyse the ester bonds of water-insoluble substrates such as triacylglycerols (triglycerides), phospholipids and cholesteryl esters. The lipase gene family originally included LPL (lipoprotein lipase), HL (hepatic lipase) and pancreatic lipase. The genes encoding these lipases have similar exon/intron boundaries, and the proteins have significant amino acid sequence similarity, which led to the proposal that they have evolved from a common ancestor. Recent studies have implicated two other lipolytic enzymes as closely related members of this lipase gene family, namely endothelial lipase and phosphatidylserine phospholipase A1 [1] (Figure 1). The human HL gene (LIPC) is located on chromosome 15q21, comprises nine exons, spans 135 kb of DNA and encodes a protein of 449 amino acids [1]. HL is a glycoprotein that catalyses the hydrolysis of triacylglycerols, phosphatidylcholines and phosphatidylethanolamines carried in different lipoproteins. LPL, HL and endothelial lipase Key words: coronary artery disease, hepatic lipase, intermediate-density lipoprotein (IDL), verylow-density lipoprotein (VLDL). Abbreviations used: apo E (etc.), apolipoprotein E (etc.); CAD, coronary artery disease; HDL, highdensity lipoprotein; HL, hepatic lipase; IDL, intermediate-density lipoprotein; LDL, low-density lipoprotein; LPL, lipoprotein lipase; TRLP, triacylglycerol-rich lipoprotein; VLDL, very-low-density lipoprotein. 1 To whom correspondence should be addressed ( iodza@tin.it). show different tissue specificity and substrate affinity. In addition, different lipoprotein classes appear to be specific for each enzyme (Table 1). The majority of HL is synthesized and secreted by the liver, and is bound to heparan sulphate proteoglycans on the surfaces of sinusoidal endothelial cells and the external surfaces of microvilli of parenchymal cells in the space of Disse. The localization of HL in the liver is relevant to its functions in lipoprotein metabolism. For instance, removal of chylomicron remnants takes place in parenchymal cells, and an endothelial localization of HL would make its potential role in this process quite complex. Therefore the localization of HL at the luminal side of the liver parenchymal cells (hepatocytes) is in accordance with its known metabolic functions. HL is a key enzyme involved in lipoprotein metabolism. Its catalytic activity contributes to the remodelling of VLDL (very-low-density lipoprotein) remnants, LDL (lowdensity lipoprotein) and HDL (high-density lipoprotein). In addition to its lipolytic activity, HL participates, with surface proteoglycans and the LDL receptor like-protein, as a ligand in promoting the hepatic uptake of lipoproteins, including remnants, LDL and HDL particles [2 4]. Both the catalytic and ligand activities of HL play a major role in promoting the scavenger receptor B1-mediated uptake of HDL-cholesteryl ester. Thus, HL may contribute to the process of reverse
2 Triglyceride-Rich Lipoproteins and Atherosclerosis 1071 Table 1 Human lipases involved in lipoprotein metabolism EL, endothelial lipase; TG, triacylglycerol; PL, phospholipid. LPL HL EL Chromosome 8p22 15q41 Substrate specificity TG > PL TG = PL PL > TG Cofactor Yes: apo CII No No (?) Preferred substrate Chylomicrons, VLDL IDL, HDL, LDL HDL Tissue localization Adipose tissue, skeletal muscle, Liver and steroid Endothelium (liver, lung, macrophages hormone-producing glands testis, thyroid, macrophages) Regulation Rapid; fasting, feeding, exercise Slower; endocrine? Half-life (h) <2 >4? Figure 1 Evolutionary relationships of the triacylglycerol lipase gene family Relationships are based on gene sequence identity. EL, endothelial lipase; PS-PLA 1,phosphatidylserine phospholipase A1; PLRP, pancreatic lipase-related protein; PL, pancreatic lipase. cholesterol transport. These effects possibly influence the process of atherosclerosis [4]. Role of HL in chylomicron/vldl remnant and LDL metabolism Plasma levels of TRLPs (triacylglycerol-rich lipoproteins) are determined by their rates of secretion from intestine (chylomicrons) and liver (VLDL), as well as by their rate of catabolism. The latter includes both triacylglycerol hydrolysis and particle uptake by cells. Catabolism of TRLP begins with the hydrolysis of core triacylglycerols by the enzyme LPL, which is synthesized primarily in adipose tissue and muscles. LPL, bound to endothelial heparan sulphate proteoglycans, interacts with TRLPs on the luminal surface of vascular endothelial cells. Thereby the initial steps of TRLP lipolysis take place in the capillary beds of adipose tissue, skeletal muscles and the heart. The smaller chylomicron and VLDL remnants resulting from the initial lipolysis by LPL are then able to permeate the fenestrate endothelium that separates the hepatocyte surface and the space of Disse from the circulation [5]. LDL receptors and the LDL receptorrelated protein on the surface of the hepatocytes clear the remnant lipoproteins via an interaction with apo E (apolipoprotein E) on the chylomicron remnants and with either apo E or apo B100 on the VLDL remnants [5]. Proteoglycans on the cell surface also play an important role in TRLP remnant uptake by the liver [6]. Hepatic clearance seems to be the final step in chylomicron metabolism, while both hepatic clearance and conversion into IDL (intermediatedensity lipoprotein) and LDL are alternative pathways for the metabolism of VLDL remnants [7]. HL plays a key role in both the uptake of TRLP remnants and their conversion into IDL and LDL, acting both as a ligand and as an enzyme in these processes. Effects of HL catalytic activity Human as well as animal studies have shown that HL is involved in the metabolism of apo B100-containing lipoproteins. Multiple lines of evidence suggest that human HL modulates the lipid composition of VLDL remnants and large, buoyant LDL, resulting in denser lipoprotein particles
3 1072 Biochemical Society Transactions (2003) Volume 31, part 5 Figure 2 Shift of lipoprotein density in patients with HL deficiency compared with normal subjects CE, cholesteryl ester; TG, triacylglycerol. both in patients with cardiovascular disease and in normal subjects [8,9]. Direct evidence that HL plays a key role in human lipoprotein metabolism is obtained from studies of individuals with HL deficiency. Few patients with true HL deficiency have been identified [10], but a detailed study of the lipoprotein phenotype in these patients and their family members supports the concept that HL activity is essential for normal lipoprotein metabolism. Patients with complete HL deficiency present with elevated plasma cholesterol and triacylglycerol concentrations, and with a lipoprotein profile characterized by the presence of large β-vldl, indicating a defect in VLDL remnant metabolism, as well as large, buoyant triacylglycerol- and phospholipid-enriched LDL and HDL (Figure 2). These large LDL particles contain apo B100 as their main apoprotein and very little, if any, apo E, truly representing a metabolic end-product of the apo B- containing lipoprotein cascade in these HL-deficient patients. Moreover, incubation of these large, buoyant LDL-like particles from an HL-deficient subject with active human HL results in the formation of LDL of normal density and lipid composition [11]. This enzyme appears to be rate limiting for the hydrolysis of triacylglycerol in these lipoproteins. Demant and co-workers [12], employing stable isotope techniques, reported in HL-deficient humans a 50% diminished conversion of small VLDL (VLDL remnants) into IDL and a near-complete absence of IDL-to-LDL conversion. This is consistent with the development of a type III-like lipoprotein profile described in HL-deficient subjects [10]. IDL-like lipoproteins also accumulate in conditions characterized by decreased HL activity, such as hypothyroidism [13]. IDL is a major determinant of CAD (coronary artery disease) risk [14], and accumulation of these lipoproteins in the presence of low HL activity might lead to increased atherosclerosis. An additional mechanism by which HL, by modulating TRLP metabolism, may affect atherosclerosis is postprandial lipid clearing. Chylomicron remnants are considered to be highly atherogenic. HL may promote postprandial lipid (chylomicron-remnant) clearing via several mechanisms, both dependent on and independent of its lipolytic activity [15]. In addition, species with low HL activity are prone to develop dietary hyperlipidaemia. Rabbits, for example, readily develop diet-induced hypercholesterolaemia, which is attenuated by overexpression of HL [16]. The influence of HL on these processes may reflect an anti-atherogenic potential of the protein. On the other hand, HL also promotes the formation of atherogenic small, dense LDL particles: the higher the HL activity, the smaller, denser and more atherogenic the LDL particles [8]. LDL triacylglycerols originate from triacylglycerol-rich VLDL in exchange for cholesteryl esters under the influence of the cholesteryl ester transfer protein. Hydrolysis of these LDL triacylglycerols by HL results in the formation of small, dense LDL. In hypertrygliceridaemic men with CAD and with a family history of CAD who participated in the FATS study, a decrease in HL activity associated with big, buoyant LDL particles correlated with adecrease in coronary stenosis [17]. It thus appears that, in humans, HL activity is not related unambiguously to the risk, presence or progression of CAD. HL as a ligand for lipoprotein uptake Recent evidence, in humans, provides support for the concept that HL indeed plays an important role in lipoprotein metabolism independent of its enzymic activity [18]. That study evaluated three patients with complete HL deficiency. All three patients had buoyant LDL compared with normal
4 Triglyceride-Rich Lipoproteins and Atherosclerosis 1073 Figure 3 Lipoprotein profile by density gradient ultracentrifugation in patients with HL deficiency HLact /prot +, no plasma HL activity but a detectable amount of inactive HL protein; HLact /prot,noplasmahlactivity and no HL protein. Adapted from [18] with permission. c (2000) The American Society for Biochemistry and Molecular Biology. individuals. Two of the patients were characterized by having neither plasma HL activity nor detectable HL protein (HLact /HLprot ); the third subject had no plasma HL activity, but did have a detectable amount (35.5 ng/ml) of HL protein (HLact /HLprot + ) (Figure 3). Despite expressing a relatively small amount of inactive protein (20% of the HL protein mass found in normal subjects), the HLact /HLprot + patient had less cholesterol in the VLDL and IDL elution range compared with the HLact /HLprot patients. Furthermore, the VLDL and IDL apo B concentrations, reflecting the number of circulating VLDL and IDL particles, were several-fold higher in the HLact /HLprot patients. These data suggest that even small amounts of inactive HL protein may significantly affect human VLDL and IDL catabolism, as observed previously in vitro and in animal models. The HLact /HLprot + patient (with the inactive protein) had higher levels of HDL-cholesterol than the HLact /HLprot patients. This finding differs from previous observations in animal models, where expression of inactive HL had only a minimal effect on HDL levels [19] or was associated with a decrease only in the apo AII-containing subclass of HDL [20]. All HL-deficient subjects showed a several-fold increase in lipoprotein triacylglycerol content across the lipoprotein density spectrum (VLDL, IDL, LDL and HDL) as compared with control subjects. Therefore inactive HL protein appears to affect VLDL and IDL particle concentration, while HL enzymic activity seems to influence VLDL, IDL, LDL and HDL triacylglycerol content and physical properties [18]. Recently, evidence has been published on the presence and synthesis of HL in human macrophages [21], a finding that may help to clarify the role of HL in atherogenesis, with implications for VLDL remnant and IDL particle metabolism. Macrophage expression of a related lipase, LPL, has been suggested to play an essential role in the progression of atherosclerotic lesions by promoting lipoprotein internalization and lipid accumulation by macrophages [22]. Like LPL, macrophage-synthesized HL may also contribute to foam cell formation and promote atherosclerosis by enhancing monocyte recruitment and retention in the arterial wall and facilitating the retention of VLDL remnants, IDL and small, dense LDL in the subendothelial space. In addition, HL synthesized in macrophages may enhance the uptake of these atherogenic lipoproteins into macrophages, suggesting a localized pro-atherogenic function for HL in the arterial wall. TRLPs and atherosclerosis: clinical implications of HL-mediated metabolism TRLPs have been implicated in clinical coronary disease events for over 40 years. Triacylglycerol-enriched apo B- containing lipoproteins have been isolated from human atherosclerotic lesions [23]. Evidence for toxicity in endothelial cells of lipolytic products of TRLPs has been reported by Chung and Segrest [24]. More recently, these investigators have identified liposomal particles within arterial lesions that have characteristics similar to those of phospholipid- and apo AI-enriched particles formed during the in vitro lipolysis of TRLPs [25]. These observations raise the possibility that the HL-mediated uptake or intra-arterial formation (see discussion of macrophage-synthesized HL above) of such lipolytic remnants could contribute to the development of atherosclerotic disease. Studies of the transport of lipoprotein particles into the rabbit aorta have demonstrated that, whereas influx was greatest for small lipoproteins, the retention of lipoproteins within arterial tissue was greatest for VLDL particles of up to 750 Å in size, a range that includes LDL, IDL and larger VLDL species [26]. Although findings in HL-deficient patients indicate that the lipolytic action of this enzyme contributes to modulation of the atherosclerotic process, recent evidence [21] supports its role in the retention/formation of VLDL remnants, IDL and possibly small, dense LDL by the arterial wall [27]. Experimental evidence strongly supports a similar role for macrophage-derived LPL [28]. Therefore the interaction of arterial HL with TRLPs may also promote retention of these particles and their lipolytic products. Remnant lipoprotein and IDL metabolism is related to human atherosclerosis in vivo. IntheMonitored Atherosclerosis Regression Study (MARS), an association between coronary artery lesion progression and the mass of all major lipoprotein fractions was observed across the VLDL IDL spectrum, as measured by analytical ultracentrifugation [29]. In contrast, no significant relationship was found between coronary artery lesion progression and the bulk of LDL mass. A more recent analysis from the MARS trial has shown that the progression of carotid artery intima-media thickness was significantly correlated with on-trial levels of IDL mass, but not with levels of the VLDL, LDL or HDL fractions [30]. Moreover, in multivariate models that included other lipoprotein predictors of carotid intima-media
5 1074 Biochemical Society Transactions (2003) Volume 31, part 5 thickness progression, including total/hdl cholesterol ratio, plasma apo B and plasma apo E, IDL mass was the only variable that showed a significant relationship. TRLPs are associated with CAD events and with the progression/regression of coronary atherosclerosis. TRLP remnants and IDL appear to be most closely related to changes in mild/moderate lesions. It appears that clinical events most commonly derive from lesions that are initially of mild or moderate severity and which suddenly undergo a transformation to a severe culprit lesion [31]. Thus impaired TRLP catabolism, as occurs in the presence of low HL activity, may be particularly important in the progression to clinical CAD events. Accumulation of TRLPs is typically associated with other lipoprotein abnormalities, specifically the presence of small, dense LDL and lower HDL-cholesterol levels, which are commonly found in association with an increased risk of CAD. Conclusions By modulating the metabolism of apo B100-containing lipoproteins, HL may have pro- as well as anti-atherogenic effects. Either enzymically or as a binding protein, it may change the level, the composition and/or the metabolism of lipoproteins in a more or a less atherogenic direction. In the presence of hypertriglyceridaemia or an increased LDL concentration, the pro-atherogenic effect of high HL activity (the formation of small, dense LDL) may prevail: the presence of high concentrations of small, dense and atherogenic LDL may override the potential beneficial effects of high HL levels on VLDL remnant and IDL metabolism. However, among individuals with low levels of LDL, having high levels of HL may not be atherogenic (since the potential of having high concentrations of small, dense LDL is low), but rather anti-atherogenic due to the enhanced catabolism of VLDL remnants and IDL. Although the role of HL as an anti- or pro-atherogenic factor is still controversial, there is convincing evidence that HL plays a key role in the remodelling of TRLP remnants, LDL and HDL. The anti- or pro-atherogenic role of HL is likely to be modulated by the concurrent presence of other lipid abnormalities (i.e. LDL-cholesterol levels), as well as by the genetic regulation of other enzymes involved in lipoprotein metabolism. References 1 Perret, B., Mabile, L., Martinez, L., Terce, F., Barbaras, R. and Collet, X. (2002) J. Lipid Res. 43, Lambert, G., Chase, M.B., Dugi, K., Bensadoun, A., Brewer, Jr, H.B. and Santamarina-Fojo, S. (1999) J. Lipid Res. 40, Dugi, K.A., Amar, M.J., Haudenschild, C.C., Shamburek, R.D., Bensadoun, A., Hoyt, Jr, R.F., Fruchart-Najib, J., Madj, Z., Brewer, Jr, H.B. and Santamarina-Fojo, S. (2000) Arterioscler. Thromb. Vasc. Biol. 20, Jansen, H., Verhoeven, J.M. and Sijbrands, E.J.G. (2002) J. Lipid Res. 43, Cooper, A.D. (1997) J. Lipid Res. 38, Mahley, R.W. and Ji, Z.S. (1999) J. Lipid Res. 40, Ginsberg, H.N., Dixon, J.L. and Goldberg, I.J. (1999) in Lipoprotein in Health and Disease (Betteridge, D.J., Illingworth, R. and Shepherd, J., eds), pp , Arnold Publishers, London 8 Zambon, A., Austin, M.A., Brown, B.G., Hokanson, J.E. and Brunzell, J.D. (1993) Arterioscler. Thromb. 13, Watson, T., Caslake, M., Freeman, D., Griffin, B., Hinnie, J., Packard, C. and Sheperd, J. (1994) Arterioscler. Thromb. 14, Brunzell, J.D. and Deeb, S.S. (2001) in The Metabolic and Molecular Basis of Inherited Disease (Scriver, C., Beaudet, A., Sly, W. and Vale, D., eds), pp , McGraw-Hill Book Co., New York 11 Auwerx, J., Marzetta, C.A., Hokanson, J.E. and Brunzell, J.D. (1989) Arteriosclerosis 9, Demant, T., Carlson, L.A., Holmquist, L., Karpe, F., Nilsson-Ehle, P., Packard, C.J. and Shepherd, J. (1988) J. Lipid Res. 29, Asami, T., Ciomartan, T. and Uchiyama, M. (1999) Pediatr. Int. 41, Krauss, R.M. (1987) Am. Heart J. 113, Yu, K.C. and Cooper, A.D. (2001) Front. Biosci. 6, Fan, J., Wang, J., Bensadoun, A., Lauer, S.J., Dang, Q., Mahley, R.W. and Taylor, J.M. (1994) Proc. Natl. Acad. Sci. U.S.A. 91, Zambon, A., Hokanson, J.E., Brown, B.G. and Brunzell, J.D. (1999) Circulation 99, Zambon, A., Deeb, S.S., Bensadoun, A., Foster, K.E. and Brunzell, J.D. (2000) J. Lipid Res. 41, Dichek, H.L., Brecht, W., Fan, J., Ji, Z.S., McCormick, S.P., Akeefe, H., Conzo, L., Sanan, D.A., Weisgraber, K.H., Young, S.G. et al. (1998) J. Biol. Chem. 273, Dugi, K.A., Amar, M.J., Haudenschild, C.C., Shamburek, R.D., Bensadoun, A., Hoyt, Jr, R.F., Fruchart-Najib, J., Madj, Z., Brewer, Jr, H.B. and Santamarina-Fojo, S. (2000) Arterioscler. Thromb. Vasc. Biol. 20, Gonzales-Navarro, H., Nong, Z., Freeman, L., Bensadoun, A., Peterson, K. and Santamarina-Fojo, S. (2002) J. Lipid Res. 43, Babaev, V.R., Patel, M.B., Semenkovich, C.F., Fazio, S. and Linton, M.F. (2000) J. Biol. Chem. 275, Rapp, J.H., Lespine, A., Hamilton, R.L., Colyvas, N., Chaumeton, A.H., Tweedie-Hardman, J., Kottie, L., Kunitake, S.T., Havel, R.J. and Kane, J.P. (1994) Arterioscler. Thromb. Vasc. Biol. 14, Chung, B.H. and Segrest, J.P. (1991) Adv. Exp. Med. Biol. 285, Chung, B.H., Tallis, G., Yalamoori, V., Anantharamaiah, G.M. and Segrest, J.P. (1994) Arterioscler. Thromb. 14, Nordestgaard, B.G. (1996) Curr. Opin. Lipidol. 7, Aviram, M., Bierman, E.L. and Chait, A. (1988) J. Biol. Chem. 263, Van Eck, M., Zimmermann, R., Groot, P.H.E., Zechner, R. and van Berckel, T.J.C. (2000) Arterioscler. Thromb. Vasc. Biol. 20, e53 e62 29 Mack, W.J., Krauss, R.M. and Hodis, H.N. (1996) Arterioscler. Thromb. Vasc. Biol. 16, Hodis, H.N., Mack, W.J., Dunn, M., Liu, C.R., Selzer, R.H. and Krauss, R.M. (1997) Circulation 95, Brown, B.G. and Fuster, V. (1996) in Atherosclerosis and Coronary Disease (Fuster, V., Ross, R. and Topol, E.J., eds), pp , Lippincott-Raven, Philadelphia Received 16 June 2003
High density lipoprotein metabolism
High density lipoprotein metabolism Lipoprotein classes and atherosclerosis Chylomicrons, VLDL, and their catabolic remnants Pro-atherogenic LDL HDL Anti-atherogenic Plasma lipid transport Liver VLDL FC
More informationPlasma lipoproteins & atherosclerosis by. Prof.Dr. Maha M. Sallam
Biochemistry Department Plasma lipoproteins & atherosclerosis by Prof.Dr. Maha M. Sallam 1 1. Recognize structures,types and role of lipoproteins in blood (Chylomicrons, VLDL, LDL and HDL). 2. Explain
More informationLipoproteins Metabolism
Lipoproteins Metabolism LEARNING OBJECTIVES By the end of this Lecture, the student should be able to describe: What are Lipoproteins? Describe Lipoprotein Particles. Composition of Lipoproteins. The chemical
More informationRole of apolipoprotein B-containing lipoproteins in the development of atherosclerosis Jan Borén MD, PhD
Role of apolipoprotein B-containing lipoproteins in the development of atherosclerosis Jan Borén MD, PhD Our laboratory focuses on the role of apolipoprotein (apo) B- containing lipoproteins in normal
More informationBehind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL
Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Sung-Joon Lee, PhD Division of Food Science Institute of Biomedical Science and Safety Korea University Composition of Lipoproteins:
More informationChapter VIII: Dr. Sameh Sarray Hlaoui
Chapter VIII: Dr. Sameh Sarray Hlaoui Lipoproteins a Lipids are insoluble in plasma. In order to be transported they are combined with specific proteins to form lipoproteins: Clusters of proteins and lipids.
More informationANSC/NUTR 618 LIPIDS & LIPID METABOLISM Lipoprotein Metabolism
ANSC/NUTR 618 LIPIDS & LIPID METABOLISM Lipoprotein Metabolism I. Chylomicrons (exogenous pathway) A. 83% triacylglycerol, 2% protein, 8% cholesterol plus cholesterol esters, 7% phospholipid (esp. phosphatidylcholine)
More informationMetabolism and Atherogenic Properties of LDL
Metabolism and Atherogenic Properties of LDL Manfredi Rizzo, MD, PhD Associate Professor of Internal Medicine Faculty of Medicine, University of Palermo, Italy & Affiliate Associate Professor of Internal
More informationLipids digestion and absorption, Biochemistry II
Lipids digestion and absorption, blood plasma lipids, lipoproteins Biochemistry II Lecture 1 2008 (J.S.) Triacylglycerols (as well as free fatty acids and both free and esterified cholesterol) are very
More informationPathophysiology of Lipid Disorders
Pathophysiology of Lipid Disorders Henry Ginsberg, M.D. Division of Preventive Medicine and Nutrition CHD in the United States CHD is the single largest killer of men and women 12 million have history
More informationLipoproteins Metabolism Reference: Campbell Biochemistry and Lippincott s Biochemistry
Lipoproteins Metabolism Reference: Campbell Biochemistry and Lippincott s Biochemistry Learning Objectives 1. Define lipoproteins and explain the rationale of their formation in blood. 2. List different
More informationCoronary artery disease (CAD) is a major cause of
Brief Review Hepatic Lipase, Lipoprotein Metabolism, and Atherogenesis Silvia Santamarina-Fojo, Herminia González-Navarro, Lita Freeman, Elke Wagner, Zengxuan Nong Abstract The role of hepatic lipase as
More information1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones?
1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones? 3How are dietary lipids transported? 4How lipids synthesized in the liver are transported? 5 Lipoprotien
More informationNature Genetics: doi: /ng.3561
Supplementary Figure 1 Pedigrees of families with APOB p.gln725* mutation and APOB p.gly1829glufs8 mutation (a,b) Pedigrees of families with APOB p.gln725* mutation. (c) Pedigree of family with APOB p.gly1829glufs8
More informationThe New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk
The New Gold Standard for Lipoprotein Analysis Advanced Testing for Cardiovascular Risk Evolution of Lipoprotein Testing The Lipid Panel Total Cholesterol = VLDL + LDL + HDL Evolution of Lipoprotein Testing
More informationLipid/Lipoprotein Structure and Metabolism (Overview)
Lipid/Lipoprotein Structure and Metabolism (Overview) Philip Barter President, International Atherosclerosis Society Centre for Vascular Research University of New South Wales Sydney, Australia Disclosures
More information行政院國家科學委員會補助專題研究計畫成果報告
NSC892314B002270 898 1 907 31 9010 23 1 Molecular Study of Type III Hyperlipoproteinemia in Taiwan β β ε E Abstract β Type III hyperlipoproteinemia (type III HLP; familial dysbetalipoproteinemia ) is a
More informationMeasurement of Serum Intermediate Density Lipoproteins (Remnant-like Particles) Original Policy Date
MP 2.04.22 Measurement of Serum Intermediate Density Lipoproteins (Remnant-like Particles) Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with
More informationUnit IV Problem 3 Biochemistry: Cholesterol Metabolism and Lipoproteins
Unit IV Problem 3 Biochemistry: Cholesterol Metabolism and Lipoproteins - Cholesterol: It is a sterol which is found in all eukaryotic cells and contains an oxygen (as a hydroxyl group OH) on Carbon number
More informationThe bridging-function of hepatic lipase reduces both apo-b48-and apo-b100- containing lipoproteins in LDL receptor deficient apo-b48-only and apo-
The bridging-function of hepatic lipase reduces both apo-b48-and apo-b100- containing lipoproteins in LDL receptor deficient apo-b48-only and apo- B100-only mice. Helén L. Dichek 1, Kun Qian, and Nalini
More informationCHAPTER FORTY FIVE ENDOGENOUS LIPID TRANSPORT PATHWAY: VLDL AND IDL
CHAPTER FORTY FIVE ENDOGENOUS LIPID TRANSPORT PATHWAY: VLDL AND IDL You will notice that the endogenous pathway is very similar to the exogenous pathway What is the average daily amount of triacylglycerol
More informationLipid Metabolism Prof. Dr. rer physiol. Dr.h.c. Ulrike Beisiegel
Lipid Metabolism Department of Biochemistry and Molecular Biology II Medical Center Hamburg-ppendorf 1 Lipids. visceral fat. nutritional lipids 0 1.5 3 4.5 9 h. serum lipids. lipid accumulation in the
More information2.5% of all deaths globally each year. 7th leading cause of death by % of people with diabetes live in low and middle income countries
Lipid Disorders in Diabetes (Diabetic Dyslipidemia) Khosrow Adeli PhD, FCACB, DABCC Head and Professor, Clinical Biochemistry, The Hospital for Sick Children, University it of Toronto Diabetes A Global
More informationCholesterol and its transport. Alice Skoumalová
Cholesterol and its transport Alice Skoumalová 27 carbons Cholesterol - structure Cholesterol importance A stabilizing component of cell membranes A precursor of bile salts A precursor of steroid hormones
More informationLipid Metabolism in Familial Hypercholesterolemia
Lipid Metabolism in Familial Hypercholesterolemia Khalid Al-Rasadi, BSc, MD, FRCPC Head of Biochemistry Department, SQU Head of Lipid and LDL-Apheresis Unit, SQUH President of Oman society of Lipid & Atherosclerosis
More informationLipid metabolism in familial hypercholesterolemia
Lipid metabolism in familial hypercholesterolemia Khalid Al-Rasadi, BSc, MD, FRCPC Head of Biochemistry Department, SQU Head of Lipid and LDL-Apheresis Unit, SQUH President of Oman society of Lipid & Atherosclerosis
More informationDisclosures. Background 1 What is Known MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES. Background 2 What is Not Known 10/2/2017
Disclosures MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES Grants: NIH, Quest Diagnostics Consultant: Quest Diagnostics Merck Global Atherosclerosis Advisory Board Ronald M. Krauss, Children s Hospital
More information5. THE ROLE OF LIPIDS IN THE DEVELOPMENT OF ATHEROSCLEROSIS AND CORONARY HEART DISEASE: GUIDELINES FOR DIAGNOSIS AND TREATMENT
5. THE ROLE OF LIPIDS IN THE DEVELOPMENT OF ATHEROSCLEROSIS AND CORONARY HEART DISEASE: GUIDELINES FOR DIAGNOSIS AND TREATMENT Prof. Victor Blaton, Ph.D. Department of Clinical Chemistry, Hospital AZ Sint-Jan
More informationHepatic lipase deficiency decreases the selective uptake of HDL-cholesteryl esters in vivo
Hepatic lipase deficiency decreases the selective uptake of HDL-cholesteryl esters in vivo Gilles Lambert, 1, * Marcelo J. A. Amar,* Pascal Martin,* Jamila Fruchart-Najib, Bernhard Föger,* Robert D. Shamburek,*
More informationJMSCR Vol 05 Issue 05 Page May 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i5.193 Lipid Profile as Early Predictor of Complication
More informationREAGENTS. RANDOX sdldl CHOLESTEROL (sdldl-c) SIZE MATTERS: THE TRUE WEIGHT OF RISK IN LIPID PROFILING
REAGENTS RANDOX sdldl CHOLESTEROL (sdldl-c) SIZE MATTERS: THE TRUE WEIGHT OF RISK IN LIPID PROFILING Randox sdldl Cholesterol (sdldl-c) Size Matters: The True Wight of Risk in Lipid Profiling 1. BACKGROUND
More informationMETHODS. Proc. Natl. Acad. Sci. USA Vol. 95, pp , December 1998 Medical Sciences. Contributed by Richard J. Havel, October 30, 1998
Proc. Natl. Acad. Sci. USA Vol. 95, pp. 15647 15652, December 1998 Medical Sciences Lamellar lipoproteins uniquely contribute to hyperlipidemia in mice doubly deficient in apolipoprotein E and hepatic
More informationChapter (5) Etiology of Low HDL- Cholesterol
Chapter (5) Etiology of Low HDL- Cholesterol The aim of this chapter is to summarize the different etiological factors mainly the role of life-style and different disease conditions contributing to the
More informationN-3 Fatty Acids Non-HDL-Cand LDL-C Thomas Dayspring MD, FACP
Omega or N-3 Fatty Acids (FA) significantly reduce TG synthesis and significantly deplete the TG content of VLDL particles indicated by significantly reduced V. FA are the substrate for TG synthesis. N3-FA
More informationLipoprotein Particle Profile
Lipoprotein Particle Profile 50% of people at risk for HEART DISEASE are not identified by routine testing. Why is LPP Testing The Most Comprehensive Risk Assessment? u Provides much more accurate cardiovascular
More informationLipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis
Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis Ira J. Goldberg Department of Medicine, Columbia University College of Physicians and Surgeons, 630 West 168th
More informationPPAR history of research
PPAR Rubens, 1640 PPAR history of research number of publications 3000 2000 1000 0 till now: : 16 296 publications 1985 1990 1995 2000 2005 year liver, brown adipocytes, kidney, heart, skeletal muscles,
More informationDigestion and transport of TAG by plasma lipoproteins
Digestion and transport of TAG by plasma lipoproteins Lipoproteins are multimolecular complexes of lipids and proteins, they are not macromolecules They transport lipids in the plasma because lipids are
More informationGlossary For TheFatNurse s For All Ages Series Adipocytes, also known as lipocytes and fat cells, are the cells that primarily compose adipose tissue, specialized in storing energy as fat. Apolipoprotein
More informationSummary and concluding remarks
Summary and concluding remarks This thesis is focused on the role and interaction of different cholesterol and phospholipid transporters. Cholesterol homeostasis is accomplished via a tightly regulated
More informationHypertriglyceridemia, Inflammation, & Pregnancy
Hypertriglyceridemia, Inflammation, & Pregnancy Richard L. Nemiroff, MD, FACOG, NLA Professor, Clinical Gynecology Perelman School of Medicine University of Pennsylvania Philadelphia, PA Disclosure of
More informationThere are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?
There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,
More informationA Study of Omega-3 Fatty Acid. Therapy in Patients with. Nephrotic Syndrome
A Study of Omega-3 Fatty Acid Therapy in Patients with Nephrotic Syndrome Dr Samira Siddiqui Renal Unit Glasgow Royal Infirmary Thesis for the degree of MD, Faculty of Medicine, University of Glasgow Submitted
More informationLIPIDS OF BLOODSTREAM
HEC No. 1428 ISSN No. 1681-5491 CARDIOLOGY MEDICAL CHANNEL Vol. 15, No. 2 APRIL - JUNE 2009 EDITORIAL LIPIDS OF BLOODSTREAM 1. ZAFAR ALAM MAHMOOD 2. SYED WASEEMUDDIN AHMED 3. MOHAMMAD SUALEH 4. SAAD BIN
More informationHepatic lipase facilitates the selective uptake of cholesteryl esters from remnant lipoproteins in apoe-deficient mice
Hepatic lipase facilitates the selective uptake of cholesteryl esters from remnant lipoproteins in apoe-deficient mice Marcelo J. A. Amar, 1, * Klaus A. Dugi,* Changting C. Haudenschild,* Robert D. Shamburek,*
More informationCholesterol metabolism. Function Biosynthesis Transport in the organism Hypercholesterolemia
Cholesterol metabolism Function Biosynthesis Transport in the organism Hypercholesterolemia - component of all cell membranes - precursor of bile acids steroid hormones vitamin D Cholesterol Sources: dietary
More informationAcetyl CoA HMG CoA Mevalonate (C6) Dimethylallyl Pyrophosphate isopentenyl Pyrophosphate (C5) Geranyl Pyrophosphate (C10) FarnesylPyrophosphate (C15) Squalene (C30) Lanosterol (C30) 7 Dehydrocholesterol
More informationMetabolism of lipoproteins containing apolipoprotein B in hepatic lipase-deficient mice
Metabolism of lipoproteins containing apolipoprotein B in hepatic lipase-deficient mice Shiqiang Qiu,* Nathalie Bergeron,* Leila Kotite,* Ronald M. Krauss, Andre Bensadoun, and Richard J. Havel 1, * Cardiovascular
More informationPart 1 Risk Factors and Atherosclerosis. LO1. Define the Different Forms of CVD
Week 3: Cardiovascular Disease Learning Outcomes: 1. Define the difference forms of CVD 2. Describe the various risk factors of CVD 3. Describe atherosclerosis and its stages 4. Describe the role of oxidation,
More informationGlossary For TheFatNurse s For All Ages Series Apolipoprotein B (APOB or ApoB) are the primary apolipoproteins of chylomicrons and low-density lipoproteins (LDL - known commonly by the misnomer "bad cholesterol"
More informationNiacin Metabolism: Effects on Cholesterol
Niacin Metabolism: Effects on Cholesterol By Julianne R. Edwards For Dr. William R. Proulx, PhD, RD Associate Professor of Nutrition and Dietetics In partial fulfillments for the requirements of NUTR342
More informationThe apolipoprotein story
Atherosclerosis Supplements 7 (2006) 23 27 The apolipoprotein story Frank M. Sacks a,b, a Department of Nutrition, Harvard School of Public Health, Boston, MA, USA b Department of Medicine, Harvard Medical
More informationHypertriglyceridemia. Ara Metjian, M.D. Resident s Report 20 December 2002
Hypertriglyceridemia Ara Metjian, M.D. Resident s Report 20 December 2002 Review of Lipids Chylomicrons (CM): Dietary lipids absorbed through the GI tract are assembled intracellularly into CM. Very Low
More informationBACKGROUND: The association between
DOI: 10.18585/inabj.v9i1.266 Association between Cardiovascular Risk and Elevated Triglycerides (Sargowo D, et al.) REVIEW ARTICLE The Association between Cardiovascular Risk and Elevated Triglycerides
More informationANTIHYPERLIPIDEMIA. Darmawan,dr.,M.Kes,Sp.PD
ANTIHYPERLIPIDEMIA Darmawan,dr.,M.Kes,Sp.PD Plasma lipids consist mostly of lipoproteins Spherical complexes of lipids and specific proteins (apolipoproteins). The clinically important lipoproteins, listed
More informationreview Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E
review Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E Robert W. Mahley 1, *, and Zhong-Sheng Ji* Gladstone Institute of Cardiovascular
More informationCentral role of apociii
University of Copenhagen & Copenhagen University Hospital Central role of apociii Anne Tybjærg-Hansen MD DMSc Copenhagen University Hospital and Faculty of Health and Medical Sciences, University of Copenhagen,
More informationRole of Small Dense Low-Density Lipoprotein in Coronary Artery Disease Patients With Normal Plasma Cholesterol Levels. Small Dense KATAGIRI, MD, FJCC
J Cardiol 2000 ; 36: 371 378 Small Dense Role of Small Dense Low-Density Lipoprotein in Coronary Artery Disease Patients With Normal Plasma Cholesterol Levels Shinji Tsutomu Taro Keiko Takeshi Minoru Hiroshi
More informationThe crucial roles of apolipoproteins E and C-III in apob lipoprotein metabolism in normolipidemia and hypertriglyceridemia
The crucial roles of apolipoproteins E and C-III in apob lipoprotein metabolism in normolipidemia and hypertriglyceridemia The Harvard community has made this article openly available. Please share how
More informationHepatic lipase expression in macrophages contributes to atherosclerosis in apoe-deficient and LCAT-transgenic mice
Hepatic lipase expression in macrophages contributes to atherosclerosis in apoe-deficient and LCAT-transgenic mice Zengxuan Nong, 1 Herminia González-Navarro, 1 Marcelo Amar, 1 Lita Freeman, 1 Catherine
More informationLipids, lipoproteins and cardiovascular disease
Lipids, lipoproteins and cardiovascular disease Presented by Dr. Mohammad Saadeh The requirements for the Clinical Chemistry Philadelphia University Faculty of pharmacy Cardiovascular disease Plasma enzymes
More informationLIPID METABOLISM. Sri Widia A Jusman Department of Biochemistry & Molecular Biology FMUI
LIPID METABOLISM Sri Widia A Jusman Department of Biochemistry & Molecular Biology FMUI Lipid metabolism is concerned mainly with fatty acids cholesterol Source of fatty acids from dietary fat de novo
More informationHypertriglyceridemia: Why, When, and How to Treat. Gregory Cohn, MD, FNLA, FASPC
Hypertriglyceridemia: Why, When, and How to Treat Gregory Cohn, MD, FNLA, FASPC DISCLOSURES Consultant to Akcea Therapeutics (in the past 12 months). OUTLINE I. Lipoproteins II. Non-HDL-C III. Causes and
More information13/09/2012. Dietary fatty acids. Triglyceride. Phospholipids:
CARDIOVASCULAR DISEASES (CVD) and NUTRITION Major cause of morbidity & mortality in Canada & other developed countries e.g., majority of approved health claims on food labels relate to lowering CVD Relation
More informationEndothelial Lipase Is Synthesized by Hepatic and Aorta Endothelial Cells and Its Expression Is Altered in apoe Deficient Mice
Endothelial Lipase Is Synthesized by Hepatic and Aorta Endothelial Cells and Its Expression Is Altered in apoe Deficient Mice Kenneth C-W. Yu, Christopher David, Sujata Kadambi, Andreas Stahl, Ken-Ichi
More informationTHE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS
THE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS Hormonal regulation INSULIN lipid synthesis, lipolysis CORTISOL lipolysis GLUCAGON lipolysis GROWTH HORMONE lipolysis CATECHOLAMINES lipolysis LEPTIN catabolism
More informationByung Hong Chung 1, * and Nassrin Dashti
Lipolytic remnants of human VLDL produced in vitro: effect of HDL levels in the lipolysis mixtures on the apocs to apoe ratio and metabolic properties of VLDL core remnants Byung Hong Chung 1, * and Nassrin
More informationMoh Tarek + Suhayb. Tamara Al-Azzeh + Asmaa Aljeelani ... Faisal
28 Moh Tarek + Suhayb Tamara Al-Azzeh + Asmaa Aljeelani... Faisal Digestion of dietary lipids Lipid digestion and absorption are complex processes. They involve soluble enzymes, substrates with different
More informationALTERATIONS IN LIPID METABOLISM IN PATIENTS OF THYROID HYPERFUNCTION
ALTERATIONS IN LIPID METABOLISM IN PATIENTS OF THYROID HYPERFUNCTION *Shashi A. and Sharma N. Department of Zoology and Environemental Sciences, Punjabi University, Patiala-147002, Punjab, India *Author
More informationPodcast (Video Recorded Lecture Series): Lipoprotein Metabolism and Lipid Therapy for the USMLE Step One Exam
Podcast (Video Recorded Lecture Series): Lipoprotein Metabolism and Lipid Therapy for the USMLE Step One Exam Howard J. Sachs, MD www.12daysinmarch.com Email: Howard@12daysinmarch.com Podcast (Video Recorded
More informationThe inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema
The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema Dept Cardiology, Leiden University Medical Center, Leiden,
More informationlipoprotein receptor (low density lipoprotein-related protein/receptor-associated protein/cholesteryl esters)
Proc. Natl. Acad. Sci. USA Vol. 92, pp. 4611-4615, May 1995 Medical Sciences Initial hepatic removal of chylomicron remnants is unaffected but endocytosis is delayed in mice lacking the low density lipoprotein
More informationBIOCHEMISTRY BLOOD - SERUM Result Range Units
BIOCHEMISTRY BLOOD - SERUM Result Range Units LIPIDS CHOLESTEROL 3.9 0.0-5.5 mmol/l TRIGLYCERIDES 0.7 < 1.5 mmol/l LIPID STUDIES HDL(Protective) 1.5 > 1.2 mmol/l LDL(Atherogenic) 2.1 0.5-3.5 mmol/l Cholesterol/HDL
More informationSTRUCTURE AND METABOLISM Of LIPIDS AND LIPOPROTEINS. R. Mohammadi Biochemist (Ph.D.) Faculty member of Medical Faculty
STRUCTURE AND METABOLISM Of LIPIDS AND LIPOPROTEINS R. Mohammadi Biochemist (Ph.D.) Faculty member of Medical Faculty STRUCTURE OF LIPIDS AND LIPOPROTEINS DEFINTITION: Compounds Insoluble in water But
More informationHepatic lipase (HL) and apoe both have critical roles in
Overexpression of Human Hepatic Lipase and ApoE in Transgenic Rabbits Attenuates Response to Dietary Cholesterol and Alters Lipoprotein Subclass Distributions Carlo M. Barbagallo, Jianglin Fan, Patricia
More informationLipid profile in Diabetes Mellitus
International Journal of Biotechnology and Biochemistry ISSN 0973-2691 Volume 13, Number 2 (2017) pp. 123-131 Research India Publications http://www.ripublication.com Lipid profile in Diabetes Mellitus
More informationBIOL2171 ANU TCA CYCLE
TCA CYCLE IMPORTANCE: Oxidation of 2C Acetyl Co-A 2CO 2 + 3NADH + FADH 2 (8e-s donated to O 2 in the ETC) + GTP (energy) + Heat OVERVIEW: Occurs In the mitochondrion matrix. 1. the acetyl portion of acetyl-coa
More informationTopic 11. Coronary Artery Disease
Topic 11 Coronary Artery Disease Lipid metabolism http://news.bbc.co.uk/2/hi/health/7372495.stm Sterol Metabolism and Coronary Artery Disease Big Picture: Exogenous Cholesterol and Fat Metabolism Fats-Triglycerides
More informationWalter B. Bayubay CLS (ASCP), AMT, MA Ed, CPI
Walter B. Bayubay CLS (ASCP), AMT, MA Ed, CPI Biochemical Analysis (Lipid Panel) Analyte Total Cholesterol Reference Range Patient A < 200 241 LDL-C /= 40 38 Triglycerides
More informationLipoprotein Pathophysiology. Lipoprotein Pathophysiology
Lipoprotein Pathophysiology Genetic Dyslipidemia Thomas A. Hughes, M.D. Professor of Medicine Division of Endocrinology, Metabolism, and Diabetes University of Tennessee Health Science Center GW is a 47
More informationPLASMA LIPOPROTEINS AND LIPIDS DETERMINATION OF PLASMA CHOLESTEROL AND TRIGLICERIDE LEVEL
PLASMA LIPOPROTEINS AND LIPIDS DETERMINATION OF PLASMA CHOLESTEROL AND TRIGLICERIDE LEVEL Lipids are characterized by low polarity and limited solubility in water. Their plasma concentration is about 500-600
More informationWhat Else Do You Need to Know? Presenter Disclosure Information. Case 1: Cardiovascular Risk Assessment in a 53-Year-Old Man. Learning Objectives
9: 1:am Understanding Dyslipidemia Testing and Screening: Importance of Lipoprotein Particle Analysis SPEAKER Matthew Sorrentino, MD, FACC Presenter Disclosure Information The following relationships exist
More informationNew Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines
Clin. Cardiol. Vol. 26 (Suppl. III), III-19 III-24 (2003) New Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines H. BRYAN BREWER, JR, M.D. Molecular
More informationStatus of Small Dense LDL in Fasting and Nonfasting Lipidemia in Coronary Heart Disease
www.jmscr.igmpublication.org Impact Factor 1.1147 ISSN (e)-2347-176x Status of Small Dense LDL in Fasting and Nonfasting Lipidemia in Coronary Heart Disease Authors Pranshi Mishra¹, Neelima Singh²,Puneet
More informationDiabetic dyslipidaemia: from basic research to clinical practice*
Diabetologia (2003) 46:733 749 DOI 10.1007/s00125-003-1111-y Review Diabetic dyslipidaemia: from basic research to clinical practice* M.-R. Taskinen Department of Medicine, Division of Cardiology, University
More informationInvestigations on the mechanism of hypercholesterolemia observed in copper deficiency in rats
J. Biosci., Vol. 12, Number 2, June 1987, pp. 137 142. Printed in India. Investigations on the mechanism of hypercholesterolemia observed in copper deficiency in rats P. VALSALA and P. A. KURUP Department
More informationATP III (Adult Treatment Panel III) CLASSIFICATION C IN ADULTS
LABORATORY AND RISK FACTORS OF ATHEROSCLEROSIS S R. Mohammadi Biochemist (Ph.D.) Faculty member of Medical Faculty RISK FACTORS FOR CHD Clinical Risk Factors Laboratory Risk Factors MAJOR CLINICAL RISK
More informationCharacterization of the lipolytic activity of endothelial lipase
Characterization of the lipolytic activity of endothelial lipase Mary G. McCoy, Gwo-Shing Sun, Dawn Marchadier, Cyrille Maugeais, Jane M. Glick, 1 and Daniel J. Rader Department of Medicine, University
More informationHepatic uptake of chylomicron remnants
Hepatic uptake of chylomicron remnants Allen D. Cooper Research Institute, Palo Alto Medical Foundation, 860 Bryant Street, Palo Alto, CA 94301, and Department of Medicine, Stanford University, Stanford,
More informationLIPID METABOLISM AND ISCHAEMIC HEART DISEASE IN THE ELDERLY
Geriatric-Cardiology Conference 75 tenance digoxin and analysed in relation to digoxin dose and renal function. In patients with normal renal function (serum creatinine less than 2 mg/100 ml, or serum
More informationCholesterol Metabolism
Cholesterol Metabolism Lippincott s Illustrated Review Chapter 18 Steroid Nucleus 1 2 Cholesterol was isolated from gall bladder stones in 1774 3 Sources and Elimination of Cholesterol Synthesis: 1000
More informationHyperlipidemia. Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi
Hyperlipidemia Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi Outline The story of lipids Definition of hyperlipidemia Classification of hyperlipidemia Causes of hyperlipidemia
More informationEzetimibe: a selective inhibitor of cholesterol absorption
European Heart Journal Supplements (2001) 3 (Supplement E), E6 E10 Ezetimibe: a selective inhibitor of cholesterol absorption Dipartimento di Scienze Farmacologiche, Universita degli Studi di Milano, Milano,
More informationEzetimibe: a selective inhibitor of cholesterol absorption
European Heart Journal Supplements (2001) 3 (Supplement E), E6 E10 Ezetimibe: a selective inhibitor of cholesterol absorption Dipartimento di Scienze Farmacologiche, Universita degli Studi di Milano, Milano,
More informationCholesterol (blood, plasma, serum)
1 Cholesterol (blood, plasma, serum) 1 Name and description of analyte 1.1 Name of analyte Cholesterol (plasma; also blood, serum) 1.2 Alternative names 2,15-dimethyl-14-(1,5-dimethylhexyl)tetracyclo[8.7.0.0
More informationLIPOPROTEINE ATEROGENE E ANTI-ATEROGENE ATEROGENE
LIPOPROTEINE ATEROGENE E ANTI-ATEROGENE ATEROGENE Sebastiano Calandra Dipartimento di Scienze Biomediche Università di Modena e Reggio Emilia Incidence Rate/1000 200-150 - 100-50 - Women 0 Men
More informationPlasma lipid transfer proteins
Plasma lipid transfer proteins Alan R. Tall Department of Medicine, College of Physicians and Surgeons of Columbia University, 630 West 168th Street, New York, NY 10032 Introduction The composition of
More informationAntihyperlipidemic Drugs
Antihyperlipidemic Drugs Hyperlipidemias. Hyperlipoproteinemias. Hyperlipemia. Hypercholestrolemia. Direct relationship with acute pancreatitis and atherosclerosis Structure Lipoprotein Particles Types
More informationsad EFFECTIVE DATE: POLICY LAST UPDATED:
Medical Coverage Policy Measurement of Small Low Density Lipoprotein Particles sad EFFECTIVE DATE: 02 16 2010 POLICY LAST UPDATED: 10 15 2013 OVERVIEW Lipoprotein-associated phospholipase A2 (Lp-PLA2),
More information